Outcome of Board Meeting held on May 09, 2026
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies Ltd reported strong FY2026 results with consolidated total income of ₹7,806 million, up 16.5% from ₹6,700 million in FY2025. Net profit grew 29.6% to ₹1,736 million, with EPS of ₹15.08 versus ₹11.72 prior year. The Board recommended a final dividend of ₹1.35 per share (67.5% payout) but deferred an interim dividend to preserve capital for potential strategic actions. Auditors MSKA & Associates issued an unmodified opinion confirming clean financials. Key appointments include reappointment of Whole-time Director Mukund Kabra and new Independent Director Pradip Shah. The company allotted 49,350 equity shares under ESOP scheme, increasing paid-up capital to ₹22.4 million. Exceptional items of ₹113.59 million were recognized due to new labour code implementation (₹47.81 million net of tax impact), partially offset by reversal of a ₹161.39 million legal provision for a US lawsuit.
Strong profitability growth with 29.6% PAT increase reflects solid operational performance. Clean audit opinion and positive operating cashflow of ₹1,568 million support financial health. Deferred interim dividend signals capital preservation for strategic initiatives.